AstraZeneca PLC (STO:AZN)
1,554.00
-5.50 (-0.35%)
Oct 31, 2025, 12:59 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B USD in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.49
Revenue / Employee
$599.16K
Employees
94,300
Market Cap
2.41T SEK
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 35.85B |
| Swedish Orphan Biovitrum AB | 27.85B |
| Medicover AB | 25.22B |
| Elekta AB | 17.84B |
| Asker Healthcare Group AB | 15.88B |
| AddLife AB | 10.53B |
| Nolato AB | 9.57B |
| Vitrolife AB | 3.51B |
AstraZeneca News
- 1 day ago - Megacap earnings to dominate next week as government shutdown continues. 11/3/25 - CME Group
- 2 days ago - AstraZeneca (AZN) Begins Phase 3 Trial for Enhertu in Lung Cancer Treatment - GuruFocus
- 2 days ago - FTSE Index shares to watch next week: BT, BP, IAG, AstraZeneca, Marks & Spencer - Invezz
- 2 days ago - Inside Celosphere 2025: Why there’s no ‘enterprise AI’ without process intelligence - VentureBeat
- 3 days ago - AstraZeneca (AZN) Reports Positive Phase 3 Trial Results for Gefurulimab - GuruFocus
- 3 days ago - FDA Streamlines Biosimilar Development; Impacts AstraZeneca (AZN) - GuruFocus
- 3 days ago - AstraZeneca Shares Surge 3% on Blockbuster Oncology Data and $2 Billion Buyback Boost - ABC Money
- 4 days ago - Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors - Nasdaq